News
Public · Published
Cumberland Pharmaceuticals Inc. (CPIX) Plans Rolling NDA for Ifetroban in DMD Cardiomyopathy
Cumberland Pharmaceuticals plans to seek FDA approval through a rolling NDA, which means submitting application sections in stages, for ifetroban to treat cardiomyopathy in Duchenne muscular dystrophy. It proposes using the Phase 2 FIGHT DMD trial plus natural history comparators as pivotal support.
Published:
Updated:
What happened
Cumberland Pharmaceuticals plans to seek FDA approval through a rolling NDA, which means submitting application sections in stages, for ifetroban to treat cardiomyopathy in Duchenne muscular dystrophy. It proposes using the Phase 2 FIGHT DMD trial plus natural history comparators as pivotal support.
Confirmed
Global impact / market context
If FDA accepts the Phase 2 trial with natural history comparators as pivotal evidence, Cumberland could reach a regulatory decision faster. However, the FDA previously suggested a Phase 3 trial, so this regulatory path carries meaningful approval risk for the company.
Analyst inference
The drug has Orphan, Rare Pediatric, and Fast Track designations, which may speed review and add exclusivity. A rare pediatric disease priority review voucher, which can be sold, could add value. The safety database covers over 1,400 subjects, reducing safety review risk.
Analyst inference
What to watch
- FDA granted a rolling NDA review, which could speed up the review schedule and potentially bring forward approval timelines if the submitted application sections are acceptable to the agency. Confirmed
- Cumberland plans to file for Traditional Approval rather than accelerated approval, which means it must meet a higher evidence bar, affecting the label and future sales. Proposed
- FDA acceptance of the NDA and agreement that Phase 2 plus natural history data provide substantial evidence is the key catalyst, since reliance on Phase 2 and registries is a regulatory risk. Analyst inference
Evidence
- Original source link unavailable